Feasibility study of stereotactic body radiotherapy for metastatic vertebral body tumor

Feasibility study of stereotactic body radiotherapy for metastatic vertebral body tumor - Feasibility study of SBRT for metastatic vertebral body tumor

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013428

Enrollment

Registered

2014-03-14

Start date

2014-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic vertebral body tumor

Interventions

stereotactic body radiotherapy (24 Gy/2 fractions or 24 Gy/3 fractions) for metastatic vertebral body tumor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) ECOG PS; 0-1. 2) RPA score Group 1 or Group 2. 3) A solitary spine metastasis or two contiguous spine levels involved. 4) No previous radiation to target. 5) Lesion which is made diagnoses with MRI within 12 weeks. 6) Pathologically-confirmed cancer. 7) Patient who can keep position while treatment. 8) Patient who can understand and write informed consent in Japanese. 9) Lesion whisc is stable in SINS score.

Exclusion criteria

Exclusion criteria: 1) Patient who cannot get MRI 2) Patient who has uncontrolled collagen disease, cardiac disease, respiratory disease or liver disorders. 3) Patient who has progressive neural symptom 4) Lesion which has cord compression grade 2 or 3. 5) Lesion which has vertebral compression fracture. 6) Patient who had chemotherapy with in 1 week before SBRT.

Design outcomes

Primary

Measure	Time frame
Rate of Grade 3 or worse adverse effects after 6 months from treatment.	—

Countries

Japan

Contacts

Public ContactHiroshi Tanaka

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital Division of Radiation Oncology

hirostan@cick.jp03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026